+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Doxorubicin - Global Strategic Business Report

  • PDF Icon

    Report

  • 288 Pages
  • March 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5302837

Global Doxorubicin Market to Reach $1.7 Billion by 2030

The global market for Doxorubicin estimated at US$1.1 Billion in the year 2022, is projected to reach a revised size of US$1.7 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2022-2030. Breast Cancer, one of the segments analyzed in the report, is projected to record 5.6% CAGR and reach US$374.1 Million by the end of the analysis period. Growth in the Lung Cancer segment is estimated at 7.4% CAGR for the next 8-year period.

The U.S. Market is Estimated at $443.5 Million, While China is Forecast to Grow at 8% CAGR

The Doxorubicin market in the U.S. is estimated at US$443.5 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$145 Million by the year 2030 trailing a CAGR of 8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.3% and 5.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Select Competitors (Total 59 Featured)

  • Merck KGaA
  • Glenmark Pharmaceuticals Ltd.
  • Fresenius Kabi AG
  • Fresenius SE & Co. KGaA
  • Natco Pharma Limited
  • Meiji Holdings Co., Ltd.
  • Celsion Corporation
  • Health Biotech Ltd.
  • MicroBiopharm Japan Co., Ltd.
  • Accord Healthcare Ltd.
  • Olon S.p.A.
  • Seqens SAS
  • Biovencer Healthcare Private Limited
  • Avacta Group
  • CSPC Pharmaceutical Group Limited

Economic Outlook

The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US trillion economy by 2030, surpassing Japan and Germany.

The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.

Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

What`s New?

  • Special discussions on the global economic climate and market sentiment
  • Coverage on global competitiveness and key competitor percentage market shares
  • Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and trademarked research platform
  • Complimentary updates for one year
  • Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes
Frequently Asked Questions about the Doxorubicin Market

What is the estimated value of the Doxorubicin Market?

The Doxorubicin Market was estimated to be valued at $1.1 Billion in 2022.

What is the growth rate of the Doxorubicin Market?

The growth rate of the Doxorubicin Market is 5.6%, with an estimated value of $1.7 Billion by 2030.

What is the forecasted size of the Doxorubicin Market?

The Doxorubicin Market is estimated to be worth $1.7 Billion by 2030.

Who are the key companies in the Doxorubicin Market?

Key companies in the Doxorubicin Market include Merck KGaA, Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, Fresenius SE & Co. KGaA, Natco Pharma Limited, Meiji Holdings Co., Ltd., Celsion Corporation, Health Biotech Ltd., MicroBiopharm Japan Co., Ltd. and Accord Healthcare Ltd..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Doxorubicin - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Cancer - An Insight
  • Cancer Treatment
  • Chemotherapy: An Overview
  • An Introduction to Doxorubicin
  • Impact of Covid-19 and a Looming Global Recession
  • World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
  • COVID-19 Impact on Global Doxorubicin Market
  • GLOBAL MARKET OVERVIEW
  • Global Doxorubicin Market Set to Witness Rapid Growth
  • US Dominates the Doxorubicin Market, Asia-Pacific to Witness Fastest Growth
  • Breast Cancer Constitutes the Largest Application for Doxorubicin
  • Competition
  • New Entrants Seek Opportunities
  • Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rise in Cancer Incidence to Drive Market Growth
  • Breakdown of Total Number of Cancer Cases by Region: 2020
  • Breakdown of Total Number of Cancer Cases by Type: 2020
  • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Liposomal Delivery Systems Offer Significant Benefits
  • A Review of Liposomal-Doxorubicin Preparations
  • DOX Hydrochloride
  • Ageing Demographics to Drive Demand
  • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
  • Market to Gain from Rise in Number of Breast Cancer Cases
  • Select Doxorubicin Phase IV and Phase III Completed Clinical Trials for Breast Cancer with Results: As of Dec 30, 2019
  • Increasing Prevalence and Incidence of Lung Cancer to Push the Demand for Doxorubicin
  • Age-Standardized Lung Cancer Rates for Select Countries
  • Lymphoma, Leukemia, Bladder Cancer, & Kaposi Sarcoma: Other Major Growth Areas
  • Uptrend in Healthcare Spending Drives the Doxorubicin Demand
  • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
  • Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
  • Cancer Research Spending Continues to Witness Growth
  • Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010-2019
  • NCI Funding for Cancer Research (2002, 2008, 2014 and 2020)
  • A Netherland’s Based Research Team Suggests a Variant of Doxorubicin can be Made more Effective without the Heart Damage Side Effect (2020) (The Netherlands)
  • Researchers Develop Non-Toxic and Precise Nanoscale Technology for Oncology Drug Delivery
  • Studies Show Positive Effect of Quantum Dot Enabled Doxorubicin Delivery in Lung Cancer Treatment
  • Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation
  • Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Doxorucibin
  • Combination Therapy: A Double Whammy Success
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Doxorubicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Doxorubicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 3: World 16-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 6: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 9: World 16-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 12: World 16-Year Perspective for Ovarian Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Multiple Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Multiple Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 15: World 16-Year Perspective for Multiple Myeloma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 18: World 16-Year Perspective for Liver Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 21: World 16-Year Perspective for Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Kaposi Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 23: World Historic Review for Kaposi Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 24: World 16-Year Perspective for Kaposi Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 25: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 26: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 27: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 28: World Doxorubicin Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • MARKET ANALYSIS
  • Rising Cancer Cases Spur Growth in Doxorubicin Market
  • Estimated Number of New Cancer Cases and Deaths in the US (2019)
  • Number of FDA-Approved Oncology Drugs in the US (2010-2018)
  • Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and 2018
  • Cancer Drugs as % of Drug Pipeline in the US for the Period 2010-2019
  • Personalized Medicine Gathers Momentum for Cancer Treatment in the US
  • TABLE 29: USA Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2023 & 2030
  • CANADA
  • Number of New Cancer Cases in Canada: 2019
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2023 & 2030
  • JAPAN
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • TABLE 35: Japan Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 36: Japan Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 37: Japan 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2023 & 2030
  • CHINA
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018
  • TABLE 38: China Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 39: China Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 40: China 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2023 & 2030
  • EUROPE
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • MARKET ANALYSIS
  • Rising Cancer Incidence and New Drug Development Augur Well for European Cancer Therapies Market
  • Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018
  • Number of New Cancer Cases Diagnosed (in Thousands) in the UK: 2018
  • TABLE 41: Europe Recent Past, Current & Future Analysis for Doxorubicin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 42: Europe Historic Review for Doxorubicin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 43: Europe 16-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
  • TABLE 44: Europe Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 45: Europe Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 46: Europe 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2023 & 2030
  • FRANCE
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • TABLE 47: France Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 48: France Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 49: France 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2023 & 2030
  • GERMANY
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • TABLE 50: Germany Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 51: Germany Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 52: Germany 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2023 & 2030
  • ITALY
  • TABLE 53: Italy Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 54: Italy Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 55: Italy 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • TABLE 56: UK Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 57: UK Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 58: UK 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2023 & 2030
  • SPAIN
  • TABLE 59: Spain Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 60: Spain Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 61: Spain 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2023 & 2030
  • RUSSIA
  • TABLE 62: Russia Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 63: Russia Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 64: Russia 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2023 & 2030
  • REST OF EUROPE
  • TABLE 65: Rest of Europe Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 66: Rest of Europe Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 67: Rest of Europe 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • MARKET ANALYSIS
  • An Insight into Asia-Pacific Market for Doxorubicin
  • Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for 2019
  • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for Doxorubicin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 69: Asia-Pacific Historic Review for Doxorubicin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 70: Asia-Pacific 16-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
  • TABLE 71: Asia-Pacific Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 72: Asia-Pacific Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 73: Asia-Pacific 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2023 & 2030
  • AUSTRALIA
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
  • INDIA
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
  • SOUTH KOREA
  • REST OF ASIA-PACIFIC
  • LATIN AMERICA
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
  • ARGENTINA
  • BRAZIL
  • MEXICO
  • REST OF LATIN AMERICA
  • MIDDLE EAST
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
  • IRAN
  • ISRAEL
  • SAUDI ARABIA
  • UNITED ARAB EMIRATES
  • REST OF MIDDLE EAST
  • AFRICA
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Merck KGaA
  • Glenmark Pharmaceuticals Ltd.
  • Fresenius Kabi AG
  • Fresenius SE & Co. KGaA
  • Natco Pharma Limited
  • Meiji Holdings Co., Ltd.
  • Celsion Corporation
  • Health Biotech Ltd.
  • MicroBiopharm Japan Co., Ltd.
  • Accord Healthcare Ltd.
  • Olon S.p.A.
  • Seqens SAS
  • Biovencer Healthcare Private Limited
  • Avacta Group
  • CSPC Pharmaceutical Group Limited